• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Mangoceuticals Inc.

    12/3/25 10:03:37 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care
    Get the next $MGRX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001254538
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    MANGOCEUTICALS, INC.
    SEC File Number
    001-41615
    Address of Issuer
    17130 N. Dallas Parkway, Suite 240
    DALLAS
    TEXAS
    75248
    Phone
    (214) 242-9619
    Name of Person for Whose Account the Securities are To Be Sold
    JOHNSTON EUGENE M
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common Stock
    Charles Schwab & Co
    3000 Schwab Way
    Westlake � TX � 76262
    128333148866.281390657012/03/2025
    Nasdaq


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common10/01/2023Stock GrantsIssuerCheckbox not checked12833310/01/2023Services Rendered

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Stock Grants to be sold were acquired between October 2023 through September 2025
    Date of Notice
    12/03/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    EUGENE M JOHNSTON

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $MGRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MGRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MGRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

    Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company") is issuing the following clarification regarding its press release issued earlier this morning titled "Mangoceuticals Partners with Eli Lilly and Novo Nordisk…". The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 medications, including, when medically appropriate, Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk. These programs allow Mangoceuticals patients to access, for the first time, Eli Lilly and N

    11/13/25 7:37:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals Partners with Eli Lilly and Novo Nordisk to Deliver Affordable Access to Zepbound and Wegovy for Obesity Management

    Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to announce that it has launched MangoRx Direct and PeachesRx Direct, two integrated programs that provide direct access to authentic Zepbound® (tirzepatide) from Eli Lilly and Wegovy® (semaglutide) from Novo Nordisk. These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly's LillyDirect® Se

    11/13/25 7:00:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Mangoceuticals' Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

    Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, and a pioneer in innovative wellness solutions, is excited to share groundbreaking results from field studies based on its patented antiviral compound which it refers to as "MGX-0024". The field studies were conducted by Solice International at Duraiswamy Farm in Palladam, Tamil Nadu, India. These studies, targeting respiratory diseases in chickens, like Newcastle Disease and Chronic Respiratory Disease (

    5/27/25 9:00:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO Johnston Eugene M sold $5,975 worth of shares (5,000 units at $1.20), decreasing direct ownership by 4% to 123,333 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    12/11/25 4:05:11 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    CFO Johnston Eugene M sold $11,280 worth of shares (10,000 units at $1.13), decreasing direct ownership by 7% to 128,333 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    12/9/25 5:16:13 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    Director Hamilton Alex P. sold $152,875 worth of shares (125,000 units at $1.22), decreasing direct ownership by 97% to 3,334 units (SEC Form 4)

    4 - MANGOCEUTICALS, INC. (0001938046) (Issuer)

    11/26/25 4:30:13 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    SEC Filings

    View All

    Mangoceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - MANGOCEUTICALS, INC. (0001938046) (Filer)

    12/10/25 6:40:28 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 144 filed by Mangoceuticals Inc.

    144 - MANGOCEUTICALS, INC. (0001938046) (Subject)

    12/3/25 10:03:37 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form 10-Q filed by Mangoceuticals Inc.

    10-Q - MANGOCEUTICALS, INC. (0001938046) (Filer)

    11/14/25 5:17:22 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Financials

    Live finance-specific insights

    View All

    Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent

    Dallas, TX, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, today announced the acquisition of patent number WO 2023/086647 PCT/US2022/049857, for mushroom-derived compositions and methods of treatment. This new addition to MangoRx's intellectual property portfolio highlights the Company's commitment to innovative solutions that support holistic health and wellness. The acquired patent encompasses nutraceutical compositions derived from functional mushrooms, including well-known varieties such as Cordyceps sinensi

    12/19/24 5:33:00 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024

    Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, today announced its financial results for the three and six months ending June 30, 2024, showing a significant growth in both shareholder's equity and gross revenues. During the six months ending June 30, 2024, MangoRx's shareholder equity increased to $13,829,445, compared to $774,754 as of December 31, 2023, reflecting an increase of 1,685%, or $13,054,691. A substantial

    8/15/24 9:25:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Leadership Updates

    Live Leadership Updates

    View All

    Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

    DALLAS, TX, April 25, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals Inc. (NASDAQ:MGRX) ("Mangoceuticals" or "MGRX"), a company focused on developing, marketing, and selling a variety of health and wellness products via a secure telemedicine platform under the brands MangoRx and PeachesRx, is pleased to announce that it has entered into an Intellectual Property Purchase Agreement to acquire all intellectual property, product formulations, know-how, distribution, supplier relationships and related assets of Smokeless Technology Corp. ("Smokeless Tech"), a Canadian-based pouch innovation company specializing in stimulant and functional pouches. This acquisition marks a strategic expansion into the

    4/25/25 9:00:00 AM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    $MGRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Mangoceuticals Inc.

    SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

    8/27/24 7:45:22 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13D/A filed by Mangoceuticals Inc. (Amendment)

    SC 13D/A - MANGOCEUTICALS, INC. (0001938046) (Subject)

    6/5/24 5:15:19 PM ET
    $MGRX
    Misc Health and Biotechnology Services
    Health Care